Marie-Agnes Doucey

Title: Marie-Agnes Doucey: Innovator in Immunology

Introduction

Marie-Agnes Doucey is a prominent inventor based in La Chaux-de-Fonds, Switzerland. She has made significant contributions to the field of immunology, particularly through her innovative work on bispecific antibodies. With a total of 2 patents, her research focuses on developing novel therapeutic solutions for autoimmune and proliferative diseases.

Latest Patents

One of her latest patents involves CD47-CD38 bispecific antibodies. This invention provides a novel class of bispecific heterodimeric immunoglobulins that target both a component of the human CD47 antigen and the human CD38 antigen. These antibodies are designed to treat various conditions, including cancers such as hematologic malignancies and solid tumors. Another significant patent relates to antibodies that bind to IL1RAP. This invention includes antibodies that specifically bind to human IL1RAP and may also bind to cynomolgus monkey and/or mouse IL1RAP. The use of these antibodies is aimed at diagnosing and treating human diseases.

Career Highlights

Marie-Agnes Doucey has worked with notable companies in the biotechnology sector, including Igi Therapeutics SA and Ichnos Sciences SA. Her work in these organizations has contributed to advancing research in immunotherapy and antibody development.

Collaborations

Throughout her career, she has collaborated with esteemed colleagues such as Jeremy Loyau and Thierry Monney. These partnerships have fostered innovation and have been instrumental in her research endeavors.

Conclusion

Marie-Agnes Doucey is a trailblazer in the field of immunology, with her patents paving the way for new treatments in cancer and autoimmune diseases. Her contributions continue to impact the scientific community and improve patient outcomes.